Efficacy of Radiotherapy Combined with EGFR-TKI in the Treatment of EGFR/TP53 Co-Mutated NSCLC

被引：0
|
作者：
Zeng, S. [1 ]
Wang, L. L. [1 ]
Tao, D. [1 ]
Zhou, W. [1 ]
Wu, Y. [2 ]
机构：
[1] Chongqing Univ Canc Hosp, Dept Radiat Oncol, Chongqing, Peoples R China
[2] Chongqing Univ, Coll Med, Chongqing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2189
引用
收藏
页码：E86 / E86
页数：1
相关论文
共 50 条
  • [1] EGFR-TKI FOR EGFR MUTATED NSCLC: NEW EVIDENCE
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 40 - 40
  • [2] EGFR-TKI plus brain radiotherapy versus EGFR-TKI alone in the management of EGFR-mutated NSCLC patients with brain metastases
    Dong, Kai
    Liang, Wenhua
    Zhao, Shen
    Guo, Minzhang
    He, Qihua
    Li, Caichen
    Song, Haiqing
    He, Jianxing
    Xia, Xiaojun
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 268 - +
  • [3] Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.
    Ulivi, Paola
    Canale, Matteo
    Petracci, Elisabetta
    Chiadini, Elisa
    Dazzi, Claudio
    Capelli, Laura
    Gamboni, Alessandro
    Casanova, Claudia
    Papi, Maximilian
    Mariotti, Marita
    De Luigi, Nicoletta
    Burgio, Marco Angelo
    Ludovini, Vienna
    Bennati, Chiara
    Chiari, Rita
    Calistri, Daniele
    Crino, Lucio
    Amadori, Dino
    Delmonte, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Valproic acid increased the efficacy of EGFR TKIs on EGFR/TP53 co-mutated lung cancers and downregulated mutant-p53 levels
    Hu, Mengdi
    Cheng, Hanyue
    Yang, Yijing
    Xu, Lu
    MOLECULAR CARCINOGENESIS, 2024, 63 (02) : 275 - 285
  • [5] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
  • [6] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
  • [7] EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A Meta-Analysis
    Xia, X.
    Guo, M.
    He, J.
    Liang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S382 - S382
  • [8] Concordance of Abundance for Mutational EGFR and Co-Mutational TP53 with Efficacy of EGFR-TKI Treatment in Metastatic Patients with Non-Small-Cell Lung Cancer
    Wang, Youping
    Liu, Hong
    Yu, Ningjuan
    Xiang, Xueping
    CURRENT ONCOLOGY, 2023, 30 (09) : 8464 - 8476
  • [9] Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
    Hou, Helei
    Qin, Kang
    Liang, Yu
    Zhang, Chuantao
    Liu, Dong
    Jiang, Haiping
    Liu, Kewei
    Zhu, Jingjuan
    Lv, Hongying
    Li, Tianjun
    Zhang, Xiaochun
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 5665 - 5675
  • [10] Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
    Takeda, Masayuki
    Okamoto, Isamu
    Tsurutani, Junji
    Oiso, Naoki
    Kawada, Akira
    Nakagawa, Kazuhiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (06) : 528 - 533
12345